Back to top

Image: Bigstock

Compared to Estimates, Danaher (DHR) Q2 Earnings: A Look at Key Metrics

Read MoreHide Full Article

For the quarter ended June 2026, Danaher (DHR - Free Report) reported revenue of $6.27 billion, up 5.5% over the same period last year. EPS came in at $1.94, compared to $1.80 in the year-ago quarter.

The reported revenue represents a surprise of +2.88% over the Zacks Consensus Estimate of $6.09 billion. With the consensus EPS estimate being $1.84, the EPS surprise was +5.44%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Danaher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Total Growth - Organic sales (Core): 3% compared to the 1.9% average estimate based on five analysts.
  • Total Sales- Diagnostics: $2.47 billion versus $2.33 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change.
  • Total Sales- Life Sciences: $1.88 billion versus the four-analyst average estimate of $1.79 billion. The reported number represents a year-over-year change of +5.7%.
  • Total Sales- Biotechnology: $1.92 billion versus the four-analyst average estimate of $1.95 billion. The reported number represents a year-over-year change of +3.8%.
  • Operating profit- Life Sciences: $244 million compared to the $228.43 million average estimate based on three analysts.
  • Operating profit- Biotechnology: $556 million versus $574.6 million estimated by three analysts on average.
  • Operating profit- Other: $-89 million compared to the $-88.96 million average estimate based on three analysts.
  • Operating profit- Diagnostics: $416 million compared to the $521.81 million average estimate based on three analysts.

View all Key Company Metrics for Danaher here>>>

Shares of Danaher have returned +12.9% over the past month versus the Zacks S&P 500 composite's -0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Published in